A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Part of paid clinical trials in Los Angeles, California.

Sponsor
Eli Lilly and Company
Study ID
NCT02576938
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally
  • Triamcinolone (Optional) — DRUG
    Administered topically

Study Details

The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.

Key Dates

Start date
Feb 29, 2016
Status verified
Jun 2020
Primary completion
Feb 28, 2017
Completion
Mar 31, 2017

Study Design

Enrollment
124 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Baricitinib
    Administered once daily in multiple oral dose cohorts for 16 weeks (Triamcinolone 0.1% topical also permitted)
  • Placebo Comparator: Placebo
    Administered orally once daily, for 16 weeks (Triamcinolone 0.1% topical also permitted)

Primary Outcome Measure

Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50) [ Time Frame: Week 16 ]

Locations (10)

FacilityCityStateZIPSite coordinators
Dermatology Research AssociatesLos AngelesCalifornia90045-
Forward Clinical Trials, IncTampaFlorida33624-
Medical Dermatology SpecialistsAtlantaGeorgia30342-
Northwestern UniversityChicagoIllinois60611-
Icahn School of MedicineNew YorkNew York10029-
Oregon Health and Science UniversityPortlandOregon97239-
Menter Dermatology Research InstituteDallasTexas75246-
Center for Clinical StudiesHoustonTexas77004-
Center for Clinical StudiesHoustonTexas77065-
Center for Clinical StudiesWebsterTexas77598-

Find similar trials in Los Angeles, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Dermatology Research Associates· Los Angeles, CAForward Clinical Trials, Inc· Tampa, FLMedical Dermatology Specialists· Atlanta, GANorthwestern University· Chicago, ILIcahn School of Medicine· New York, NYOregon Health and Science University· Portland, OR

Related Studies